首页
产品中心
心血管介入
外周血管介入
神经介入
非血管介入
下载专区
新闻资讯
公司新闻
行业资讯
学术论文
加入我们
公司环境
员工发展
招聘岗位
联系我们
联系方式
在线留言
EN
公司受邀参加“2017年国际植入介入医疗器械制造技术峰会”
2017年7月27—28日，由荣格集团主办的“2017年国际植入介入医疗器械制造技术峰会”在美丽的苏州金鸡湖新罗酒店举行。公司受邀参加此次会议，董事长刘青博士发表"全降解血管支架的3D打印"的主题演讲。
2017
07-31
第二十届中国北京国际科技产业博览会参展
科技部、国家知识产权局、中国贸促会和北京市政府共同主办的第二十届中国北京国际科技产业博览会(以下简称科博会)于2017年6月8-10日在中国国际展览中心开展。
06-12
董事长刘青博士参加ClemsonInternationalBiomaterialsSymposium-China会议
刘青博士应GuigenZhang教授邀请参加了4月10日在美国Clemson大学举办的InternationalBiomaterialsSymposium-China， 并做了题为 “Development of Bioresorbable Tissue Scaffolds Using A New Precision Multi-axial 3D Printing Technology” 的报告
04-14
公司赞助Chinese Association for Biomaterials（CAB,华人生物材料协会）活动
公司特赞助ChineseAssociationforBiomaterials(CAB,华人生物材料协会)活动
阿国产精品视频区a区AMSorb全降解冠脉药物洗脱支架临床试验项目启动会在西安顺利召开
阿国产精品视频区a区AMSorbTM全降解冠脉药物洗脱支架临床试验项目启动会在西安顺利召开
2016
09-09
阿国产精品视频区a区3D打印可降解冠脉血管支架亮相欧洲心脏大会
2016年8月30日在意大利罗马召开的欧洲心脏大会上，来自北京大学第一医院霍勇教授团队的郑博教授报告了阿国产精品视频区a区自主创新的3D打印可降解冠脉血管支架临床前的研究结果。引起与会者们的极大兴趣。
08-31
Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients
To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.
08-12
1-year outcomes with the Absorb bioresorbable scaff old in patients with coronary artery disease: a patient-level, pooled meta-analysis
Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention. Whether or not these devices are as safe and effective as drug-eluting stents within the first year after implantation is unknown.
First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China
To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA).
Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience
To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.
